1. Women's Health: HOLOGIC Gen-Probe is a world leader in the development and improvement of molecular diagnostic tests focused on sexually transmitted diseases (STDs) and microbial infections affecting women's health. Core products include the APTIMA reagent, which tests for Chlamydia and Gonorrhea, two of the most common bacterial sexually transmitted diseases (STDs); and the Human Papilloma Virus (HPV), the culprit of cervical cancer, as well as Trichomonas vaginalis, a parasitic STD.
2, prostate oncology: PCA3 is a gene that is detected in 95% of prostate cancer cases, the specifics of which can be analyzed by the PROGENSA PCA3 urine molecular diagnostic test.PROGENSA PCA3 has been approved by the FDA (U.S. Food and Drug Administration), the Council of the European Union, and Health Canada, and has been marketed and put into use in the above three places. The test has been approved by the FDA (U.S. Food and Drug Administration), the European Union Council, and Health Canada.
3. Virology: HOLOGICGen-Probe provides qualitative assays for the detection of Human Immunodeficiency Virus (HIV-1) and Hepatitis C Virus (HCV) in human plasma or serum. "The APTIMA HIV Qualitative Assay is the only FDA-approved assay for the diagnosis of HIV-1.
4. Assay equipment: Based on hardware and software engineering expertise, HOLOGIC Gen-Probe developed the TIGRIS instrument, the world's first and only fully automated, comprehensive, high-throughput molecular diagnostic instrumentation system, which is already on the market. First commissioned in 2004, the instrument significantly reduces labor costs and risk of contamination in high-volume diagnostic assays and ensures that donor blood is checked individually at large blood screening centers. Customers can use the TIGRIS system to test the efficacy of the APTIMA line of women's health products and to perform PROCLEIX ULTRIO, PROCLEIX ULTRIO PLUS and West Nile Virus assays to complete their blood screening. Based on the success of the TIGRIS system, HOLOGIC Gen-Probe has developed a new automated instrumentation station called the "PANTHER system" (specifically designed for low to medium volume customers), which has been approved by the FDA (U.S. Food and Drug Administration), the Council of the European Union, Health Canada, and the European Commission. The PANTHER System has been approved by the FDA (U.S. Food and Drug Administration), the European Commission, and Health Canada, and is available for sale in all three jurisdictions, and Hologic has been awarded more than 100 patents around the world in recognition of its innovations in the field of molecular diagnostic automation.
5. Blood Screening: For the PROCLEIX assay and system developed by HOLOGIC Gen-Probe, Novartis Pharmaceuticals has commercialized it worldwide. These technologies help blood banks examine donor blood and screen for potentially deadly viruses such as HIV-1, hepatitis C and B, and West Nile (WNV) virus, thereby preventing transfusion recipients from contracting these viruses.
6. Infectious Diseases: As a global leader in molecular diagnostics for infectious diseases, HOLOGIC Gen-Probe owns a number of patented technologies and products that can test for a variety of infectious microorganisms that can cause a wide range of diseases such as Sexually Transmitted Diseases (STDs), respiratory infectious diseases, Tuberculosis, Streptococcal Laryngitis, Pneumonia, and Fungal Infections. Its core products include the APTIMA assay, which tests for chlamydia and gonorrhea, human papillomavirus and Trichomonas vaginalis; and the Prodesse assay, which offers a wide range of molecular tests for different types of respiratory diseases and hospital-acquired infections.
7. Hereditary Disease Screening: Elucigene products include gel and fluorescence based devices for simple and rapid analysis of human hereditary diseases and rapid heterozygosity testing. The products have been authorized by the Council for sale in the European Union.
8. Molecular diagnostics: Diagnostic tests are an essential part of the health care process, providing important information to doctors and patients. They can also help assess a patient's risk of developing a disease, confirm a case, and help physicians determine the appropriateness of treatment or care for an established patient. Diagnostics can facilitate early diagnosis to arrive at appropriate treatments, thereby ensuring efficacy and reducing costs. Although diagnostics represent a small portion of total healthcare spending - less than 5 percent - they impact 60-70 percent of healthcare decisions.
HOLOGIC Gen-Probe developed NAT to test for unique genetic sequences of microorganisms that cause infectious diseases, infect donor blood, or cause mutations in certain cancer-causing genes. The molecular diagnostic test directly examines the unique genetic fingerprints of disease-causing agents, providing more efficient and accurate results than traditional methods such as antibody and culture tests. For example, with the HOLOGIC Gen-Probe for HIV-1 and Hepatitis C virus, the risk of contracting these high-risk diseases from blood transfusions has been reduced to approximately 1 in 2 million.